The reinforcement threshold for nicotine as a target for tobacco control

Drug and Alcohol Dependence

Volumn 125, Issue 1-2, 2012, Pages 1-7

  Sofuoglu, Mehmet ^a   LeSage, Mark G ^b  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adolescent smoking; Nicotine; Reinforcement; Tobacco addiction

Indexed keywords

NICOTINE;

CHEMICAL COMPOSITION; CIGARETTE SMOKING; CLINICAL ASSESSMENT TOOL; CONTROL STRATEGY; DISEASE SEVERITY; DSM-IV; EXPERIMENTAL ANIMAL; FAGERSTROM TEST FOR NICOTINE DEPENDENCE SCALE; HUMAN; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; REINFORCEMENT; REVIEW; SMOKING CESSATION; TOBACCO; TOBACCO DEPENDENCE;

ADOLESCENT; ANIMALS; HUMANS; NICOTINE; NICOTINIC AGONISTS; REINFORCEMENT (PSYCHOLOGY); SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

NICOTIANA TABACUM;

EID: 84864999953     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.04.023     Document Type: Review

References (99)

1. Adriani W., Macri S., Pacifici R., Laviola G. Peculiar vulnerability to nicotine oral self-administration in mice during early adolescence. Neuropsychopharmacology 2002, 27:212-224.
2. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003, 70:S55-S72.
3. Audrain-McGovern J., Nigg J.T., Perkins K.A. Endophenotypes for nicotine dependence risk at or before initial nicotine exposure. Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence 2009, U.S. Dept. of Health and HumanServices, National Institutes of Health, National Cancer Institute, Bethesda. G. Swain (Ed.).
4. Baker T.B., Conti D.V., Moffit T.E., Caspi A. The nicotine dependence-phenotype: translating theoretical perspectives and extant data into recommendations for genetic mapping. Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence 2009, U.S. Dept. of Health and HumanServices, National Institutes of Health, National Cancer Institute, Bethesda. G. Swan (Ed.).
5. Baker T.B., Piper M.E., McCarthy D.E., Bolt D.M., Smith S.S., Kim S.Y., Colby S., Conti D., Giovino G.A., Hatsukami D., Hyland A., Krishnan-Sarin S., Niaura R., Perkins K.A., Toll B.A. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob. Res. 2007, 9(Suppl. 4):S555-S570. Transdisciplinary Tobacco Use Research Center.
6. Balster R.L. Drug abuse potential evaluation in animals. Br. J. Addict. 1991, 86:1549-1558.
7. Baum S.S., Hill R., Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur. J. Pharmacol. 1996, 314:75-82.
8. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712.
9. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008, 83:531-541.
10. Benowitz N.L., Henningfield J.E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med. 1994, 331:123-125.
11. Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 2009, 192:29-60.
12. Benowitz N.L., Jacob P. Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 1984, 35:499-504.
13. Benowitz N.L., Jacob P. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J. Pharmacol. Exp. Ther. 1990, 254:1000-1005.
14. Benowitz N.L., Jacob P.I., Ahijevich K., Jarvis M.J., Hall S., LeHouzec J., Lichenstein E., Henningfield J.E., Tsoh J., Hurt R.D., Velicer W. Biochemical verification of tobacco use and cessation. Report from the SRNT Subcommittee on Biochemical Verification. Nicotine Tob. Res. 2002, 4:149-159.
15. Bierut L.J. Nicotine dependence and genetic variation in the nicotinic receptors. Drug Alcohol Depend. 2009, 104:S64-S69.
16. Britton J., Edwards R.C.I.N.L.M. Tobacco smoking, harm reduction, and nicotine product regulation. Lancet 2008, 371:441-445.
17. Caldwell B., Dickson S., Burgess C., Siebers R., Mala S., Parkes A., Crane J. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine Tob. Res. 2009, 11:342-347.
18. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 2009, 105(Suppl. 1):S14-S25.
19. Chen H., Matta S.G., Sharp B.M. Acquisition of nicotine self-administration in adolescent rats given prolonged access to the drug. Neuropsychopharmacology 2007, 32:700-709.
20. Clemens K., Caillé S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int. J. Neuropsychopharmacol. 2009, 12:1355-1366.
21. Coggins C.R., Murrelle E.L., Carchman R.A., Heidbreder C. Light and intermittent cigarette smokers: a review (1989-2009). Psychopharmacology (Berl.) 2009, 207:343-363.
22. Colby S.M., Tiffany S.T., Shiffman S., Niaura R.S. Measuring nicotine dependence among youth: a review of available approaches and instruments. Drug Alcohol Depend. 2000, 59(Suppl. 1):S23-S39.
23. Comer S.D., Ashworth J.B., Foltin R.W., Johanson C.E., Zacny J.P., Walsh S.L. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend. 2008, 96:1-15.
24. Corrigall W.A. Understanding brain mechanisms in nicotine reinforcement. Br. J. Addict. 1991, 86:507-510.
25. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 1989, 99:473-478.
26. Cox B.M., Goldstein A., Nelson W.T. Nicotine self-administration in rats. Br. J. Pharmacol. 1984, 83:49-55.
27. Center for Disease Control Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR 2008, 57:1226-1228.
28. Center for Disease Control Current cigarette smoking prevalence among working adults-United States, 2004-2010. MMWR 2011, 60:1305-1309.
29. Dale L.C., Glover E.D., Sachs D.P., Schroeder D.R., Offord K.P., Croghan I.T., Hurt R.D. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001, 119:1357-1364.
30. Donny E.C., Houtsmuller E., Stitzer M.L. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction 2007, 102:324-334.
31. Eissenberg T. Measuring the emergence of tobacco dependence: the contribution of negative reinforcement models. Addiction 2004, 99(Suppl. 1):5-29.
32. FDA Guidance for Industry: Assessment of Abuse Potential of Drugs 2010, Center for Drug Evaluation Research, Washington, DC.
33. Fidler J.A., Jarvis M.J., Mindell J., West R. Nicotine intake in cigarette smokers in England: distribution and demographic correlates. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3331-3336.
34. Fiore M.C., Jaen C.R., Baker T.B. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline 2008, Department of Health and Human Services, Rockville, MD.
35. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
36. Franken F.H., Pickworth W.B., Epstein D.H., Moolchan E.T. Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy. Cancer Epidemiol. Biomarkers Prev. 2006, 15:154-157.
37. Gartner C., Hall W. Harm reduction policies for tobacco users. Int. J. Drug Policy 2010, 21:129-130.
38. Glautier S. Measures and models of nicotine dependence: positive reinforcement. Addiction 2004, 99(Suppl. 1):30-50.
39. Harvey D.M., Yasar S., Heishman S.J., Panlilio L.V., Henningfield J.E., Goldberg S.R. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl.) 2004, 175:134-142.
40. Hatsukami D.K., Joseph A.M., Lesage M., Jensen J., Murphy S.E., Pentel P.R., Kotlyar M., Borgida E., Le C., Hecht S.S. Developing the science base for reducing tobacco harm. Nicotine Tob. Res. 2007, 9(Suppl. 4):S537-S553.
41. Hatsukami D.K., Perkins K.A., LeSage M.G., Ashley D.L., Henningfield J.E., Benowitz N.L., Backinger C.L., Zeller M. Nicotine reduction revisited: science and future directions. Tob. Control 2010, 19:e1-e10.
42. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
43. Hendricks P.S., Prochaska J.J., Humfleet G.L., Hall S.M. Evaluating the validities of different DSM-IV-based conceptual constructs of tobacco dependence. Addiction 2008, 103:1215-1223.
44. Henningfield J.E., Benowitz N.L., Slade J., Houston T.P., Davis R.M., Deitchman S.D. Reducing the addictiveness of cigarettes, Council on Scientific Affairs, American Medical Association. Tob. Control 1998, 7:281-293.
45. Henningfield J.E., Cohen C., Heishman S.J. Drug self-administration methods in abuse liability evaluation. Br. J. Addict. 1991, 86:1571-1577.
46. Henningfield J.E., Goldberg S.R. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 1983, 19:1021-1026.
47. Henningfield J.E., Keenan R.M. Nicotine delivery kinetics and abuse liability. J. Consult. Clin. Psychol. 1993, 61:743-750.
48. Henningfield J.E., Miyasato K., Jasinski D.R. Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav. 1983, 19:887-890.
49. Herman A.I., Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr. Psychiatry Rep. 2010, 12:433-440.
50. Hoffmann D., Wynder E.L. Chemical constituents and bioactivity of tobacco smoke. IARC Sci. Publ. 1986, 74:145-165.
51. Hughes J.R. Should criteria for drug dependence differ across drugs?. Addiction (Abingdon, England) 2006, 101(Suppl. 1):134-141.
52. Hughes J.R., Helzer J.E., Lindberg S.A. Prevalence of DSM/ICD-defined nicotine dependence. Drug Alcohol Depend. 2006, 85:91-102.
53. Hughes J.R., Higgins S.T., Bickel W.K. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 1994, 89:1461-1470.
54. Hughes J.R., Oliveto A.H., Riggs R., Kenny M., Liguori A., Pillitteri J.L., MacLaughlin M.A. Concordance of different measures of nicotine dependence: two pilot studies. Addict. Behav. 2004, 29:1527-1539.
55. Karahanian E., Quintanilla M.E., Tampier L., Rivera-Meza M., Bustamante D., Gonzalez-Lira V., Morales P., Herrera-Marschitz M., Israel Y. Ethanol as a prodrug: brain metabolism of ethanol mediates its reinforcing effects. Alcohol Clin. Exp. Res. 2011, 35:606-612.
56. Kessler D. Letter to the Coalition on Smoking or Health February, 1994.
57. Lee L.Y., Burki N.K., Gerhardstein D.C., Gu Q., Kou Y.R., Xu J. Airway irritation and cough evoked by inhaled cigarette smoke: role of neuronal nicotinic acetylcholine receptors. Pulm. Pharmacol. Ther. 2007, 20:355-364.
58. Lerman C., Perkins K.A., Gould T.J. Nicotine dependence endophenotypes in chronic smokers. Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence 2009, U.S. Dept. of Health and HumanServices, National Institutes of Health, National Cancer Institute, Bethesda. G. Swan (Ed.).
59. Levin E.D., Rezvani A.H., Montoya D., Rose J.E., Swartzwelder H.S. Adolescent-onset nicotine self-administration modeled in female rats. Psychopharmacology (Berl.) 2003, 169:141-149.
60. Levine A., Huang Y., Drisaldi B., Griffin E.A., Pollak D.D., Xu S., Yin D., Schaffran C., Kandel D.B., Kandel E.R. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci. Transl. Med. 2011, 3:107-109.
61. Lundeen R.E. Tobacco under the FDA: a summary of the Family Smoking Prevention and Tobacco Control Act. Health Care Law Mon. 2009, 9:2-9.
62. Lunell E., Molander L., Ekberg K., Wahren J. Site of nicotine absorption from a vapour inhaler-comparison with cigarette smoking. Eur. J. Clin. Pharmacol. 2000, 55:737-741.
63. Marshall L., Schooley M., Ryan H., Cox P., Easton A., Healton C., Jackson K., Davis K.C., Homsi G. Youth tobacco surveillance-United States, 2001-2002. MMWR Surveill. Summ. 2006, 55:1-56.
64. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardiner P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., Mccallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothenfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 2007, 190:269-319.
65. McKim W.A. Drugs and Behavior: An Introduction to Behavioral Pharmacology 2007, Pearson/Prentice Hall, Upper Saddle River.
66. McQuown S., Dao J., Belluzzi J., Leslie F. Age-dependent effects of low-dose nicotine treatment on cocaine-induced behavioral plasticity in rats. Psychopharmacology 2009, 207:143-152.
67. McQuown S.C., Belluzzi J.D., Leslie F.M. Low dose nicotine treatment during early adolescence increases subsequent cocaine reward. Neurotoxicol. Teratol. 2007, 29:66-73.
68. Moolchan E.T., Radzius A., Epstein D.H., Uhl G., Gorelick D.A., Cadet J.L., Henningfield J.E. The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers?. Addict. Behav. 2002, 27:101-113.
69. Naqvi N.H., Bechara A. The airway sensory impact of nicotine contributes to the conditioned reinforcing effects of individual puffs from cigarettes. Pharmacol. Biochem. Behav. 2005, 81:821-829.
70. O'Connor E.C., Chapman K., Butler P., Mead A.N. The predictive validity of the rat self-administration model for abuse liability. Neurosci. Biobehav. Rev. 2011, 35:912-938.
71. Parascandola M. Tobacco harm reduction and the evolution of nicotine dependence. Am. J. Public Health 2011, 101:632-641.
72. Perkins K.A. Discriminative stimulus effects of nicotine in humans. Handb. Exp. Pharmacol. 2009, 192:369-400.
73. Perkins K.A., Donny E., Caggiula A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1999, 1:301-315.
74. Perkins K.A., Fonte C., Sanders M., Meeker J., Wilson A. Threshold doses for nicotine discrimination in smokers and non-smokers. Psychopharmacology (Berl.) 2001, 155:163-170.
75. Piper M.E., McCarthy D.E., Baker T.B. Assessing tobacco dependence: a guide to measure evaluation and selection. Nicotine Tob. Res. 2006, 8:339-351.
76. Pollay R.W., Dewhirst T.C.I.N.T.C.M. The dark side of marketing seemingly " Light" cigarettes: successful images and failed fact. Tob. Control 2002, 11(Suppl. 1):I18-I31.
77. Rommelspacher H., Meier-Henco M., Smolka M., Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 2002, 441:115-125.
78. Rose J.E. The role of upper airway stimulation in smoking. Prog. Clin. Biol. Res. 1988, 261:95-106.
79. Rose J.E. Disrupting nicotine reinforcement: from cigarette to brain. Ann. NY Acad. Sci. 2008, 1141:233-256.
80. Rose J.E., Behm F.M., Westman E.C., Bates J.E. Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol. Biochem. Behav. 2003, 76:307-313.
81. Rose J.E., Corrigall W.A. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 1997, 130:28-40.
82. Rose J.S., Dierker L.C. DSM-IV nicotine dependence symptom characteristics for recent-onset smokers. Nicotine Tob. Res. 2010, 12:278-286.
83. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology 1999, 145:1-20.
84. Schuster C.R., Johanson C.E. An analysis of drug-seeking behavior in animals. Neurosci. Biobehav. Rev. 1981, 5:315-323.
85. Shiffman S. Tobacco " chippers" -individual differences in tobacco dependence. Psychopharmacology (Berl.) 1989, 97:539-547.
86. Shiffman S., Fischer L.B., Zettler-Segal M., Benowitz N.L. Nicotine exposure among nondependent smokers. Arch. Gen. Psychiatry 1990, 47:333-336.
87. Shiffman S., Paty J. Smoking patterns and dependence: contrasting chippers and heavy smokers. J. Abnorm. Psychol. 2006, 115:509-523.
88. Shiffman S., Sayette M.A. Validation of the nicotine dependence syndrome scale (NDSS): a criterion-group design contrasting chippers and regular smokers. Drug Alcohol Depend. 2005, 79:45-52.
89. Smith S.S., Piper M.E., Bolt D.M., Fiore M.C., Wetter D.W., Cinciripini P.M., Baker T.B. Development of the brief Wisconsin inventory of smoking dependence motives. Nicotine Tob. Res. 2010, 12:489-499.
90. Sofuoglu M., Mooney M. Subjective responses to intravenous nicotine: greater sensitivity in women than in men. Exp. Clin. Psychopharmacol. 2009, 17:63-69.
91. Sofuoglu M., Yoo S., Hill K.P., Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008, 33:715-720.
92. Sorge R., Clarke P. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. J. Pharmacol. Exp. Ther. 2009, 333:633-640.
93. Talhout R., Schulz T., Florek E., van Benthem J., Wester P., Opperhuizen A. Hazardous compounds in tobacco smoke. Int. J. Environ. Res. Public Health 2011, 8:613-628.
94. Tengs T.O., Ahmad S., Savage J.M., Moore R., Gage E. The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. Prev. Med. 2005, 40:170-180.
95. Tiffany S.T., Conklin C.A., Shiffman S., Clayton R.R. What can dependence theories tell us about assessing the emergence of tobacco dependence?. Addiction 2004, 99(Suppl. 1):78-86.
96. Warner K.E. Tobacco harm reduction: promise and perils. Nicotine Tob. Res. 2002, 4(Suppl. 2):S61-S71.
97. Watkins S.S., Epping-Jordan M.P., Koob G.F., Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 1999, 62:743-751.
98. Waxman H. Family Smoking Prevention and Tobacco Control Act 2007, House of Representatives.
99. Zins B.J., Sandborn W.J., Mays D.C., Lawson G.M., McKinney J.A., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Hurt R.D., Offord K.P., Lipsky J.J. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J. Clin. Pharmacol. 1997, 37:426-436.